Results 41 to 50 of about 224,807 (304)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer

open access: yesCell Reports, 2019
Summary: Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor
Justin H. Hwang   +31 more
doaj   +1 more source

Direct action through the Sertoli cells is essential for androgen stimulation of spermatogenesis [PDF]

open access: yes, 2010
Androgens act to stimulate spermatogenesis through androgen receptors (AR) on the Sertoli cells and peritubular myoid cells (PTM). Specific ablation of the AR in either cell type will cause a severe disruption of spermatogenesis.
Abel, M.H.   +4 more
core   +1 more source

The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis

open access: yesFrontiers in Pharmacology
BackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Jianqing Wang   +9 more
doaj   +1 more source

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers

open access: yes, 2007
Antagonists of growth hormone-releasing hormone (GHRH) could extend the duration of response of androgen sensitive prostate cancers to androgen deprivation.
Stangelberger, Anton   +8 more
core   +1 more source

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer [PDF]

open access: yesCancers, 2021
Non-steroidal anti-androgens have a major role in the treatment of non-localized prostate cancer. Interleukins are involved in the regulation of many cellular functions in prostate cancer and also modify cellular response to anti-androgens. A specific role of selected IL is presented in this review.
openaire   +2 more sources

High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor

open access: yesCells, 2020
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease ...
Hadjer Dellal   +8 more
doaj   +1 more source

Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists [PDF]

open access: yes, 2023
Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists.

core  

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

open access: yesPLoS ONE, 2013
The management of hormone-refractory prostate cancer represents a major challenge in the therapy of this tumor, and identification of novel androgen receptor antagonists is needed to render treatment more effective.
Anna Tesei   +13 more
doaj   +1 more source

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer [version 4; peer review: 2 approved]

open access: yesF1000Research
Background: Prostate cancer is a disease that occurs in men aged more than 50 years. In Iraq, 8.89 men per 100,000 population suffer from prostate cancer, with the incidence being 14,016 cases and mortality being 6,367 cases.
Hany Akeel Al-Hussaniy   +2 more
doaj   +1 more source

Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy [PDF]

open access: yes, 2023
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant

core  

Home - About - Disclaimer - Privacy